Agenus, Inc. (AGEN)
7.67
-0.42
(-5.19%)
USD |
NASDAQ |
Aug 24, 16:00
7.67
0.00 (0.00%)
After-Hours: 20:00
Agenus Enterprise Value : 609.42M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 609.42M |
| August 20, 2026 | 583.85M |
| August 19, 2026 | 616.66M |
| August 18, 2026 | 585.56M |
| August 17, 2026 | 569.36M |
| August 14, 2026 | 576.61M |
| August 13, 2026 | 562.97M |
| August 12, 2026 | 558.71M |
| August 11, 2026 | 555.72M |
| August 10, 2026 | 562.97M |
| August 07, 2026 | 561.26M |
| August 06, 2026 | 583.85M |
| August 05, 2026 | 596.21M |
| August 04, 2026 | 618.37M |
| August 03, 2026 | 597.91M |
| July 31, 2026 | 584.28M |
| July 30, 2026 | 601.75M |
| July 29, 2026 | 547.20M |
| July 28, 2026 | 545.92M |
| July 27, 2026 | 525.89M |
| July 24, 2026 | 519.50M |
| July 23, 2026 | 528.45M |
| July 22, 2026 | 500.32M |
| July 21, 2026 | 502.46M |
| July 20, 2026 | 476.46M |
| Date | Value |
|---|---|
| July 17, 2026 | 478.16M |
| July 16, 2026 | 477.74M |
| July 15, 2026 | 478.16M |
| July 14, 2026 | 481.15M |
| July 13, 2026 | 525.47M |
| July 10, 2026 | 407.42M |
| July 09, 2026 | 402.73M |
| July 08, 2026 | 403.16M |
| July 07, 2026 | 413.81M |
| July 06, 2026 | 409.98M |
| July 02, 2026 | 413.39M |
| July 01, 2026 | 409.98M |
| June 30, 2026 | 395.06M |
| June 29, 2026 | 384.05M |
| June 26, 2026 | 379.43M |
| June 25, 2026 | 373.65M |
| June 24, 2026 | 375.19M |
| June 23, 2026 | 380.97M |
| June 22, 2026 | 379.81M |
| June 18, 2026 | 378.27M |
| June 17, 2026 | 376.73M |
| June 16, 2026 | 377.50M |
| June 15, 2026 | 387.90M |
| June 12, 2026 | 389.83M |
| June 11, 2026 | 393.29M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Iovance Biotherapeutics, Inc. | 3.503B |
| Novavax, Inc. | 1.051B |
| Fate Therapeutics, Inc. | 193.81M |
| Amgen, Inc. | 280.82B |
| Anika Therapeutics, Inc. | 278.32M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.567M |
| Revenue (Quarterly) | 34.52M |
| Total Expenses (Quarterly) | 35.07M |
| EPS Diluted (Quarterly) | -0.0146 |
| Gross Profit Margin (Quarterly) | 98.50% |
| Profit Margin (Quarterly) | -1.64% |
| Earnings Yield | 34.56% |
| Operating Earnings Yield | 12.66% |
| Normalized Earnings Yield | 13.01 |